CSC Peng Yuan is concerned that Hainan Puli Pharmaceutical Co., Ltd. is unable to disclose the 2023 annual report and the first quarter report of 2024 within the legal period, and trading of the company's shares and convertible corporate bonds will be suspended from May 6, 2024. In response to the above matters, the Shenzhen Stock Exchange issued a letter of concern to the company. On May 8, 2024, the China Securities Regulatory Commission decided to file a lawsuit against the company. The above incident indicates that the company has problems with information disclosure, internal control, etc., and is expected to have a certain adverse impact on the company's operations, finances, and credit conditions. CSIC Peng Yuan will closely monitor the subsequent developments of the above events and continue to track the possible impact of the above matters on the long-term credit ratings, rating prospects, and credit ratings of related debts of company entities.
中证鹏元：关注普利制药无法如期披露定期报告、债券停牌以及收到关注函和立案告知书事项
CSC Peng Yuan: Concerned about Puli Pharmaceuticals' inability to disclose periodic reports, bond suspensions, and receipt of letters of concern and case filing notices as scheduled
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.